Combination therapy for glaucoma treatment

Details Combination therapy for glaucoma treatment Combination therapy for glaucoma treatment

2011-01-18

2011-01-18

Krass, Frederick (Department: 1612)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Ester doai

C514S063000

Reexamination Certificate

active

07872045

ABSTRACT:
A method is disclosed herein comprising administering a compound and a second drug to an eye of a mammal for the treatment of glaucoma or the reduction of intraocular pressure, said compound represented by the general formula I;wherein A, B, D, X, Y, Z, R1, R3and R4are as defined in the specification.

REFERENCES:
patent: 4994274 (1991-02-01), Chan et al.
patent: 5028624 (1991-07-01), Chan et al.
patent: 5034413 (1991-07-01), Chan et al.
patent: 5446041 (1995-08-01), Chan et al.
patent: 5627208 (1997-05-01), Stjernschantz et al.
patent: 5892099 (1999-04-01), Maruyama et al.
patent: 6043275 (2000-03-01), Maruyama et al.
patent: 6410591 (2002-06-01), Burk
patent: 2005/0209194 (2005-09-01), Burk et al.
patent: 0292870 (1988-11-01), None
patent: 0737676 (1996-10-01), None
patent: 0 855 389 (1998-07-01), None
patent: 0860430 (1998-08-01), None
patent: 0 985 663 (2000-03-01), None
patent: 0 985 663 (2000-03-01), None
patent: 09286775 (1998-02-01), None
patent: 10-265454 (1998-10-01), None
patent: 2000-1472 (2000-01-01), None
patent: 0038663 (2000-07-01), None
patent: 0038667 (2000-07-01), None
patent: WO 00/38667 (2000-07-01), None
patent: WO 02/102389 (2002-12-01), None
patent: WO 02/102389 (2002-12-01), None
patent: WO 03/047513 (2003-06-01), None
patent: WO 2006/058063 (2005-11-01), None
patent: WO 2006/055481 (2006-05-01), None
Bito, L.Z.,Biological Protection with Prostaglandins, Cohen, M.M., ed., Boca Raton, Fla, CRC Press Inc., 1985, pp. 231-252.
Bito, L.Z.,Applied Pharmacology in the Medical Treatment of Glaucomas, Drance, S.M. and Neufeld, A.H. eds, New York, Grune & Stratton, 1984, pp. 477-505.
Nilsson et al, Invest.Ophthalmol. Vis. Sci.(suppl), 284 (1987).
Bito, L.Z.,Arch. Ophthalmol.105, 1036 (1987).
Siebold et al,Prodrug5 3 1989.
Matsumura et al, “Prostaglandins having multi-substituted aryloxy groups and their use”, Derwent Publications Ltd., (Sep. 29, 1998).
Dijkstra et al, Repertorium 96/97, p. 1089-1091.
Hirano et al, “Prostaglandin derivative”, Derwent Publications Ltd., (Jun. 5, 2001).
Maruyama et al, “Design and synthesis of a highly selective EP4-receptor agonist”, Bioorganic & Medicinal Chemistry Letters (2001), 2029-2031.
Kabashima, K, The Prostaglandin Receptor EP4 Suppresses Colitis, Mucosal Damage and CD4 Cell Activation in the Gut, Apr. 2002, pp. 883-893, vol. 109 The Journal of Clinical In.
Nitta, M. Expression of the EP4 Prostaglandin E2 Receptor Subtype with Rat Detran Sodium Sulphate Colitis: Colitis Suppression by a Selective Agonist, ONO-AE1-329, Blackwell.

Affiliated with

Also associated with

Rating

Combination therapy for glaucoma treatment does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Combination therapy for glaucoma treatment, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Combination therapy for glaucoma treatment will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2675883